Ranbaxy gets TCA approval for OZIDAL Risperidone

Ranbaxy Laboratories has received an approval from the Therapeutic Goods Administration (TGA), Department of Health and Ageing of the Australian Government, for the registration of OZIDAL Risperidone 0.5, 1, 2, 3 and 4 mg tablets in Australia.

The marketing authorisation application was submitted by Ranbaxy Australia, a wholly owned subsidiary of the company.

With the approval of OZIDAL, Ranbaxy now has a total number of 27 molecules approved for marketing in Australia since the incorporation of Ranbaxy Australia in 2004 covering a wide range of therapeutic areas including anti-hypertensives, anti-infectives, hypolipidaernic agents, anti-convulsants, anti-depressants, etc.